Bevacizumab in Recurrent Grade II and III Glioma (TAVAREC)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Hoffmann-La Roche
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC
ClinicalTrials.gov Identifier:
NCT01164189
First received: July 15, 2010
Last updated: July 16, 2015
Last verified: July 2015
  Purpose

RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether temozolomide is more effective when given with or without bevacizumab in treating patients with recurrent glioma.

PURPOSE: This randomized clinical trial is studying how well temozolomide works with or without bevacizumab in treating patients with recurrent glioma.


Condition Intervention Phase
Central Nervous System Tumors
Biological: Bevacizumab
Drug: Temozolomide
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomized Trial Assessing the Significance of Bevacizumab in Recurrent Grade II and Grade III Gliomas - The TAVAREC Trial

Resource links provided by NLM:


Further study details as provided by European Organisation for Research and Treatment of Cancer - EORTC:

Primary Outcome Measures:
  • Probability of survival at 1 year [ Time Frame: From the date of randomization up to the date of death, assessed up to 12 months ] [ Designated as safety issue: No ]
    Patients alive at 12 months


Secondary Outcome Measures:
  • Objective response rate and duration of response [ Time Frame: From the date of randomization until disease progression ] [ Designated as safety issue: No ]
    Objective response includes best overall responses complete response and partial response

  • Progression-free survival [ Time Frame: From the date of randomization until the date of objective progression or the date of patient's death whichever occurs first ] [ Designated as safety issue: No ]
  • Overall survival and survival at 24 months [ Time Frame: From the date of randomization up to the date of death ] [ Designated as safety issue: No ]
  • Safety [ Time Frame: After the first ten patients in each arm have completed the first two cycles or have stopped treatment, an interim safety review of those patients will be conducted. ] [ Designated as safety issue: Yes ]
  • Clinical/neurological deterioration-free survival [ Time Frame: From the date of randomization until the date of neurological deterioration ] [ Designated as safety issue: No ]
  • Steroid use [ Time Frame: At baseline and every 3 months untill lost to follow-up ] [ Designated as safety issue: No ]
  • Quality of life of patients and caregivers/relatives [ Time Frame: At baseline and every 3 months untill lost to follow-up ] [ Designated as safety issue: No ]
  • Cognitive deterioration [ Time Frame: At baseline and every 3 months untill lost to follow-up ] [ Designated as safety issue: No ]

Estimated Enrollment: 144
Study Start Date: February 2011
Estimated Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Temozolomide
Administered orally on day 1-5, 150-200 mg/m(2), repeated every 4 weeks, up to 12 cycles
Drug: Temozolomide
Temozolomide (250, 100, 20 and 5 mg caps) will be administered orally on day 1-5, 150-200 mg/m², and will be repeated every 4 weeks. This will be repeated for up to 12 cycles.
Other Names:
  • Temodar
  • Temodal
  • Temcad
Experimental: Temozolomide + Bevacizumab

TMZ: Administered orally on day 1-5, 150-200 mg/m(2), repeated every 4 weeks, up to 12 cycles

Beva: 10 mg/kg bw IV in 90 minutes on day 1 and 14, 4 week cycles.

Biological: Bevacizumab
Bevacizumab (vial of 400mg/16mL) at a dose of 10 mg/kg bodyweight i.v. in 90 min on day 1 and day 14 of 4 week cycles
Other Name: Avastin
Drug: Temozolomide
Temozolomide (250, 100, 20 and 5 mg caps) will be administered orally on day 1-5, 150-200 mg/m², and will be repeated every 4 weeks. This will be repeated for up to 12 cycles.
Other Names:
  • Temodar
  • Temodal
  • Temcad

Detailed Description:

OBJECTIVES:

Primary

  • To document the activity of both combination temozolomide plus bevacizumab and temozolomide alone in patients with recurrent grade II or grade III glioma without 1p/19q co-deletion.

Secondary

  • To characterize the safety of treatment in these patients.
  • To document the quality of life and cognitive functioning, as a measure of clinical benefit, of these patients.
  • To explore qualification or occurrence of prognostic and/or predictive biomarkers of activity or efficacy in these patients. (exploratory)
  • To document the discordances between RANO and Macdonald's criteria for the evaluation of response and progression. (exploratory)

OUTLINE: This is a multicenter study. Patients are stratified according to institution, initial histology (grade II vs grade III), WHO performance status (0-1 vs 2), and prior treatment (radiotherapy [RT] alone, temozolomide [TMZ] or procarbazine, lomustine and vincristine [PCV] alone vs TMZ/RT). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients receive oral temozolomide as in arm I and bevacizumab IV over 90 minutes on days 1 and 15. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.

Patients complete neurocognitive questionnaires (i.e., the Hopkins Verbal Learning test, the Controlled Oral Word Association test, and the Trail Making tests A and B). Quality-of-life assessment questionnaires, including EORTC QLQ-C30 and EORTC-BN20, are completed by both patients and caregivers/relatives at baseline and then periodically.

Frozen tumor biopsies or paraffin blocks and blood specimens are collected for bio-banking and translational research.

After completion of study therapy, patients are followed up every 3 months.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
  • Histologically proven grade II or grade III astrocytoma, oligodendroglioma or oligoastrocytoma according to the WHO 2007 at initial diagnosis.
  • Demonstrated absence of 1p/19q co-deletion according to local diagnosis.
  • Availability of biological material for central review processes and translational research projects
  • First recurrence after initial treatment with either radiotherapy and/or chemotherapy.
  • Enhancing recurrence on MRI scan.
  • For non operated patients, recurrent disease must be at least one bi-dimensionally measurable contrast-enhancing lesion with clearly defined margins by MRI scan, with minimal diameters of 10 mm, visible on 2 or more axial slices 5 mm apart, based on MRI scan done within two weeks prior to start of randomisation.
  • Stable or decreasing dosage of steroids for 7 days prior to the baseline MRI scan.
  • No more than one line of chemotherapy (concurrent and adjuvant temozolomide chemotherapy is considered one line of chemotherapy)

    • If given, chemotherapy must have consisted of either temozolomide or PCV, and patients must be off chemotherapy treatment for more than 6 months without progression.
  • No radiotherapy within the three months prior to the diagnosis of progression
  • No radiotherapy with a dose over 65 Gy, stereotactic radiosurgery or brachytherapy unless the recurrence is histologically proven
  • No current or recent (within 4 weeks before randomization) treatment with another investigational drug
  • No prior treatment with Bevacizumab or other VEGF inhibitors or VEGF-Receptor signaling inhibitors
  • No invasive procedures (surgical resection, open biopsy, significant traumatic injury or any other major surgery involving entry into a body cavity) within 4 weeks prior to randomization, or anticipation of the need for major surgery during the course of the study treatment.
  • No core biopsy (excluding intracranial biopsy) or other minor surgical procedure within 7 days prior to randomization. Placement of a central vascular access device (CVAD) if performed at least 2 days prior to bevacizumab administration is allowed.
  • Patient may have undergone surgery for recurrence. If operated, residual and measurable disease after surgery is not required but histology must have confirmed the recurrence. Craniotomy or intracranial biopsy site must be adequately healed free of drainage or cellulitis, and the underlying cranioplasty must appear intact at the time of randomisation.
  • No previous other malignancies, except for any previous malignancy which was treated with curative intent more than 5 years prior to randomisation, and except for adequately controlled limited basal cell carcinoma of the skin, squamous carcinoma of the skin or carcinoma in situ of the cervix
  • Absence of any cardiovascular disorder, including but not limited to:

    • No history of myocardial infarction, unstable angina within 6 months prior to randomisation
    • No "New York Heart Association" (NYHA) Grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication.
    • No significant vascular disease (e.g. aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to randomisation
    • No prior history of hypertensive crisis or hypertensive encephalopathy
    • No inadequately controlled hypertension (defined as systolic blood pressure >150 mmHg and/or diastolic blood pressure >100 m Hg)
  • Absence of any thrombotic or hemorrhagic event, including but not limited to:

    • No evidence of recent hemorrhage on MRI of the brain. However, patients with clinically asymptomatic presence of hemosiderin, resolving hemorrhagic changes related to surgery, and presence of punctate hemorrhage in the tumor are permitted entry into the study
    • No history or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding.
    • No arterial or venous thrombosis ≤ 12 months prior to randomization
    • No history of stroke or TIAs within 6 months prior to randomization
    • No history of pulmonary haemorrhage/haemoptysis ≥ grade 2 according to the NCI-CTCAE version 4.0 criteria within 1 month prior to randomization
    • Absence of current or recent (within 10 days of first dose of Bevacizumab) use of aspirin (> 325 mg/day) or other NSAID with anti-platelet activity or treatment with dipyramidole, ticlopidine, clopidogrel or cilostaz.
    • International normalized ratio (INR) > 1.5 ULN and activated partial thromboplastin time (aPTT) > 1.5 × the ULN. Patients using full-dose anticoagulants at baseline are excluded from the study; but prevention of thrombosis with low-dose anticoagulant is allowed
  • Absence of known hypersensitivity

    • to any part of the Bevacizumab or Temozolomide formulations.
    • to Chinese hamster ovary cell products or other recombinant human or humanized antibody.
  • No underlying or previous conditions that could interfere with treatment, including but not limited to:

    • No history of intracranial abscess within 6 months prior to randomisation
    • No clinically serious (as judged by the investigator) non-healing wounds, active skin ulcers or incompletely healed bone fracture.
    • No history of active gastroduodenal ulcer(s).
    • No history of abdominal fistula as well as non-GI fistula, gastrointestinal perforation or intraabdominal abscess within 6 months prior to inclusion.
    • No evidence of active infection requiring hospitalization or antibiotics, within 2 weeks prior to randomisation.
    • No other diseases, interfering with follow up.
  • Normal hematological functions: neutrophils ≥ 1.5 x 109 cells/l, platelets ≥100 x 109 cells/l and Hb ≥ 6.2 mmol/l (9.9 g/dl).
  • Normal liver function: bilirubin < 1.5 x upper limit of the normal range (ULN), alkaline phosphatase and transaminases (ASAT) < 2.5 x ULN, INR < 1.5 ULN.
  • Normal renal function: calculated (Cockcroft-Gault) or measured creatinine clearance > 30 mL/min; Urine dipstick for proteinuria < 2+. Patients with ≥2+ proteinuria on dipstick urinalysis at baseline should undergo 24 hours urine collection and must demonstrate ≤1 g of protein/24 hr.
  • Age ≥ 18 years
  • WHO Performance status 0 - 2
  • Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized. In general, the decision for appropriate methods to prevent pregnancy should be determined by discussions between the investigator and the study subject. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal.

    • Post menopause is defined as: amenorrhea ≥ 12 consecutive months without another cause or for women with irregular menstrual periods and on hormone replacement therapy (HRT), a documented serum follicle stimulating hormone (FSH) level > 35 mIU/mL
    • Women who are using oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy, or are practicing abstinence or where their partner is sterile (eg, vasectomy) should be considered to be of childbearing potential.
    • Women of child bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to the start of investigational product.
  • Female patients within one year of entering the menopause as well as males must agree to use an effective non-hormonal method of contraception during the treatment period and for at least 6 months after the last study treatment.
  • Female should not be breast feeding
  • Absence of any psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule; such conditions should be assessed with the patient before randomization in the trial.
  • Before patient randomization and study related procedures (that would not have been performed as part as standard care), written informed consent must be given according to ICH/GCP, and national/local regulations. Informed consent should also be given for biological material to be stored and used for future research on brain tumors.
  • All indicated timelines and absolute values requested by the eligibility criteria must be adhered to. However, a maximum of +/- 10% of the reference value for laboratory parameters and a maximum of +/- 2 days for timelines may be acceptable. Discussion with Headquarters and study coordinator is encouraged.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01164189

Locations
Austria
Landesnervenklinik Wagner Jauregg
Linz, Austria
Medical University Vienna - General Hospital AKH
Vienna, Austria
Belgium
Universitair Ziekenhuis Brussel
Brussel, Belgium
U.Z. Leuven - Campus Gasthuisberg
Leuven, Belgium
France
CHU de Lyon - CHU Lyon - Hopital neurologique Pierre Wertheimer
Lyon, France
Assistance Publique - Hôpitaux de Marseille - Hôpital de La Timone
Marseille, France
CHU de Nice - Hopital Pasteur
Nice, France
CHU Pitie-Salpetriere
Paris, France
Institut Gustave Roussy
Paris, France
Centre Eugene Marquis
Rennes, France
Institut de Cancerologie de l'Ouest (ICO) - Centre Rene Gauducheau
Saint - Herblain, France
Centre Paul Strauss
Strasbourg, France
Germany
Universitaetsklinikum Bonn
Bonn, Germany
Klinikum Der J.W. Goethe Universitaet
Frankfurt am Main, Germany
Universitaetsklinikum Heidelberg - UniversitaetsKlinikum Heidelberg - Head Hospital
Heidelberg, Germany
Universitaetskliniken Regensburg
Regensburg, Germany
Israel
Rambam Medical Center
Haifa, Israel
Italy
Ospedale Bellaria
Bologna, Italy
Netherlands
Medisch Centrum Haaglanden - Westeinde
Den Haag, Netherlands
Academisch Ziekenhuis Maastricht
Maastricht, Netherlands
Radboud University Nijmegen Medical Centre
Nijmegen, Netherlands
Daniel Den Hoed Cancer Center at Erasmus Medical Center
Rotterdam, Netherlands
Switzerland
Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland
UniversitaetsSpital Zurich - Division of Oncology
Zurich, Switzerland
United Kingdom
NHS Lothian - Western General Hospital
Edinburgh, United Kingdom
Leeds Teaching Hospitals NHS Trust - St. James's University Hospital
Leeds, United Kingdom
University College Hospital
London, United Kingdom
Freeman Hospital, Northern Centre For Cancer Care
Newcastle upon Tyne, United Kingdom
Sponsors and Collaborators
European Organisation for Research and Treatment of Cancer - EORTC
Hoffmann-La Roche
Investigators
Study Chair: Martin J. van Den Bent, MD Daniel Den Hoed Cancer Center at Erasmus Medical Center
Study Chair: Ahmed Idbaih CHU Pitie-Salpetriere
  More Information

Additional Information:
No publications provided

Responsible Party: European Organisation for Research and Treatment of Cancer - EORTC
ClinicalTrials.gov Identifier: NCT01164189     History of Changes
Other Study ID Numbers: EORTC-26091, 2009-017422-39
Study First Received: July 15, 2010
Last Updated: July 16, 2015
Health Authority: Austria: Agency for Health and Food Safety
Belgium: Federal Agency for Medicinal Products and Health Products
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Federal Institute for Drugs and Medical Devices
Italy: Ethics Committee
Israel: Ethics Commission
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Switzerland: Swissmedic
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by European Organisation for Research and Treatment of Cancer - EORTC:
adult anaplastic astrocytoma
adult diffuse astrocytoma
adult pilocytic astrocytoma
adult pineal gland astrocytoma
adult subependymal giant cell astrocytoma
adult oligodendroglioma
adult anaplastic oligodendroglioma
recurrent adult brain tumor
adult giant cell glioblastoma
adult glioblastoma
adult gliosarcoma
adult mixed glioma

Additional relevant MeSH terms:
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms
Neoplasms by Site
Nervous System Diseases
Bevacizumab
Temozolomide
Alkylating Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Growth Inhibitors
Growth Substances
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on July 27, 2015